Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 2
1973 17
1974 29
1975 10
1976 17
1977 32
1978 31
1979 28
1980 31
1981 30
1982 34
1983 40
1984 54
1985 63
1986 46
1987 47
1988 77
1989 101
1990 154
1991 175
1992 216
1993 224
1994 227
1995 222
1996 174
1997 172
1998 184
1999 176
2000 156
2001 141
2002 155
2003 155
2004 428
2005 999
2006 1472
2007 1895
2008 2299
2009 2592
2010 3018
2011 3290
2012 3564
2013 3900
2014 4184
2015 4400
2016 4233
2017 4325
2018 4156
2019 2308
2020 114
Text availability
Article attribute
Article type
Publication date

Search Results

44,393 results
Results by year
Filters applied: . Clear all
Page 1
Rho-kinase inhibitors in the management of glaucoma.
Berrino E, Supuran CT. Berrino E, et al. Expert Opin Ther Pat. 2019 Oct;29(10):817-827. doi: 10.1080/13543776.2019.1670812. Epub 2019 Oct 1. Expert Opin Ther Pat. 2019. PMID: 31573364 Review.
Allosteric Small-Molecule Serine/Threonine Kinase Inhibitors.
Panicker RC, Chattopadhaya S, Coyne AG, Srinivasan R. Panicker RC, et al. Adv Exp Med Biol. 2019;1163:253-278. doi: 10.1007/978-981-13-8719-7_11. Adv Exp Med Biol. 2019. PMID: 31707707 Review.
Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target.
Alam MM, Sanchez-Azqueta A, Janha O, Flannery EL, Mahindra A, Mapesa K, Char AB, Sriranganadane D, Brancucci NMB, Antonova-Koch Y, Crouch K, Simwela NV, Millar SB, Akinwale J, Mitcheson D, Solyakov L, Dudek K, Jones C, Zapatero C, Doerig C, Nwakanma DC, Vázquez MJ, Colmenarejo G, Lafuente-Monasterio MJ, Leon ML, Godoi PHC, Elkins JM, Waters AP, Jamieson AG, Álvaro EF, Ranford-Cartwright LC, Marti M, Winzeler EA, Gamo FJ, Tobin AB. Alam MM, et al. Science. 2019 Aug 30;365(6456):eaau1682. doi: 10.1126/science.aau1682. Science. 2019. PMID: 31467193
Small molecule modulators targeting protein kinase CK1 and CK2.
Qiao Y, Chen T, Yang H, Chen Y, Lin H, Qu W, Feng F, Liu W, Guo Q, Liu Z, Sun H. Qiao Y, et al. Eur J Med Chem. 2019 Nov 1;181:111581. doi: 10.1016/j.ejmech.2019.111581. Epub 2019 Aug 1. Eur J Med Chem. 2019. PMID: 31400711 Review.
A patent review of RAF kinase inhibitors (2010-2018).
Man RJ, Zhang YL, Jiang AQ, Zhu HL. Man RJ, et al. Expert Opin Ther Pat. 2019 Sep;29(9):675-688. doi: 10.1080/13543776.2019.1651842. Epub 2019 Aug 6. Expert Opin Ther Pat. 2019. PMID: 31370713 Review.
Recent advances in the development of cyclin-dependent kinase 7 inhibitors.
Teng Y, Lu K, Zhang Q, Zhao L, Huang Y, Ingarra AM, Galons H, Li T, Cui S, Yu P, Oumata N. Teng Y, et al. Eur J Med Chem. 2019 Dec 1;183:111641. doi: 10.1016/j.ejmech.2019.111641. Epub 2019 Aug 22. Eur J Med Chem. 2019. PMID: 31514062 Review.
[Pharmacology of Janus kinase inhibitors].
Solimani F, Hilke FJ, Ghoreschi K. Solimani F, et al. Hautarzt. 2019 Dec;70(12):934-941. doi: 10.1007/s00105-019-04509-x. Hautarzt. 2019. PMID: 31740978 Review. German.
44,393 results
Jump to page
Feedback